GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cloudbreak Pharma 2592.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Cloudbreak Pharma — daily HKEX:2592

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Cloudbreak Pharma on TradingView ↗

About Cloudbreak Pharma

Its shares trade on HKEX under the ticker 2592.HK. It has been listed since 3 July 2025. In the fiscal year to 31 December 2024, it reported revenue of $10.0m and a net loss of $99.1m. At that date it held total assets of $40.0m and shareholders' equity of −$351.5m.

Cloudbreak Pharma, Inc. is an investment holding company, which engages in the research and development of therapeutic biologics. The company is headquartered in Irvine, California. The company went IPO on 2025-07-03. The firm is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The firm has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.

Figures and description from our data supplier, not checked against the company's own report.

More about Cloudbreak Pharma →

Latest on Cloudbreak Pharma

Our reporting

We have not reported on Cloudbreak Pharma yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Cloudbreak Pharma's ticker?

Cloudbreak Pharma trades as 2592.HK on HKEX, under ISIN KYG2215S1084.

What was Cloudbreak Pharma's last closing price?

We have not recorded a close for this listing yet. The chart above carries pricing from TradingView.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.